| Autor: |
Youn, Young Chul, Lee, Byoung Sub, Kim, Gwang Je, Ryu, Ji Sun, Lim, Kuntaek, Lee, Ryan, Suh, Jeewon, Park, Young Ho, Pyun, Jung-Min, Ryu, Nayoung, Kang, Min Ju, Kim, Hye Ryoun, Kang, Sungmin, An, Seong Soo A, Kim, SangYun |
| Předmět: |
|
| Zdroj: |
Journal of Alzheimer's Disease; 2020, Vol. 75 Issue 2, p493-499, 7p |
| Abstrakt: |
Background: Oligomeric amyloid-β (Aβ) is one of the major contributors to the pathomechanism of Alzheimer's disease (AD); Aβ oligomerization in plasma can be measured using a Multimer Detection System-Oligomeric Aβ (MDS-OAβ) after incubation with spiked synthetic Aβ.Objective: We evaluated the clinical sensitivity and specificity of the MDS-OAβ values for prediction of AD.Methods: The MDS-OAβ values measured using inBlood™ OAβ test in heparin-treated plasma samples from 52 AD patients in comparison with 52 community-based subjects with normal cognition (NC). The inclusion criterion was proposed by the NINCDS-ADRDA and additionally required at least 6 months of follow-up from the initial clinical diagnosis in the course of AD.Results: The MDS-OAβ values were 1.43±0.30 ng/ml in AD and 0.45±0.19 (p < 0.001) in NC, respectively. Using a cut-off value of 0.78 ng/ml, the results revealed 100% sensitivity and 92.31% specificity.Conclusion: MDS-OAβ to measure plasma Aβ oligomerization is a valuable blood-based biomarker for clinical diagnosis of AD, with high sensitivity and specificity. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
